Non Malignant Disorders

News

Palvella and Ligand partner for Phase III rare lymphatic tumour trial

Palvella Therapeutics has partnered with Ligand Pharmaceuticals for the Phase III clinical trial investigating topical Qtorin rapamycin for the treatment…

Phalguni Deswal

Sign up to the newsletter: In Brief

Your corporate email address *

First name *

Last name *

Company name *

Job title *

I would also like to subscribe to:

Pharma Technology Focus : Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

Sign up for our daily news round-up!

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Thank you for subscribing